150 related articles for article (PubMed ID: 35742035)
1. Sclerostin Concentration and Bone Biomarker Trends in Patients with Spinal Cord Injury: A Prospective Study.
Lee JH; Cho JH; Lee DG
Healthcare (Basel); 2022 May; 10(6):. PubMed ID: 35742035
[TBL] [Abstract][Full Text] [Related]
2. Periostin and sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status.
Maïmoun L; Ben Bouallègue F; Gelis A; Aouinti S; Mura T; Philibert P; Souberbielle JC; Piketty M; Garnero P; Mariano-Goulart D; Fattal C
Bone; 2019 Oct; 127():612-619. PubMed ID: 31351195
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin: a candidate biomarker of SCI-induced osteoporosis.
Morse LR; Sudhakar S; Lazzari AA; Tun C; Garshick E; Zafonte R; Battaglino RA
Osteoporos Int; 2013 Mar; 24(3):961-8. PubMed ID: 22801952
[TBL] [Abstract][Full Text] [Related]
4. Associations of serum sclerostin and polymorphisms in the SOST gene with bone mineral density and markers of bone metabolism in postmenopausal Chinese women.
He J; Zhang H; Wang C; Zhang Z; Yue H; Hu W; Gu J; Fu W; Hu Y; Li M; Liu Y; Zheng H; Zhang Z
J Clin Endocrinol Metab; 2014 Apr; 99(4):E665-73. PubMed ID: 24423318
[TBL] [Abstract][Full Text] [Related]
5. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.
Garnero P; Sornay-Rendu E; Munoz F; Borel O; Chapurlat RD
Osteoporos Int; 2013 Feb; 24(2):489-94. PubMed ID: 22525978
[TBL] [Abstract][Full Text] [Related]
6. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
[TBL] [Abstract][Full Text] [Related]
8. Association between sclerostin and bone density in chronic spinal cord injury.
Morse LR; Sudhakar S; Danilack V; Tun C; Lazzari A; Gagnon DR; Garshick E; Battaglino RA
J Bone Miner Res; 2012 Feb; 27(2):352-9. PubMed ID: 22006831
[TBL] [Abstract][Full Text] [Related]
9. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
10. Circulating sclerostin is elevated in short-term and reduced in long-term SCI.
Battaglino RA; Sudhakar S; Lazzari AA; Garshick E; Zafonte R; Morse LR
Bone; 2012 Sep; 51(3):600-5. PubMed ID: 22575440
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of serum total P1NP, β-CTX and 25(OH)D3 detection in evaluating risks of fragile hip fracture in elderly patients with osteoporosis].
Lou H; Peng C; Chen Q
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1346-9. PubMed ID: 22985580
[TBL] [Abstract][Full Text] [Related]
12. Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling.
Wu Y; Xu SY; Liu SY; Xu L; Deng SY; He YB; Xian SC; Liu YH; Ni GX
Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):470-478. PubMed ID: 28239825
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin levels and changes in bone metabolism after bariatric surgery.
Muschitz C; Kocijan R; Marterer C; Nia AR; Muschitz GK; Resch H; Pietschmann P
J Clin Endocrinol Metab; 2015 Mar; 100(3):891-901. PubMed ID: 25490275
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2015 Sep; 26(9):2273-80. PubMed ID: 25939310
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.
Invernizzi M; Carda S; Rizzi M; Grana E; Squarzanti DF; Cisari C; Molinari C; Renò F
Spinal Cord; 2015 Aug; 53(8):615-20. PubMed ID: 25896346
[TBL] [Abstract][Full Text] [Related]
16. Bone biomarkers in patients with chronic traumatic spinal cord injury.
Sabour H; Norouzi Javidan A; Latifi S; Larijani B; Shidfar F; Vafa MR; Heshmat R; Emami Razavi H
Spine J; 2014 Jul; 14(7):1132-8. PubMed ID: 24139865
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the efficacy of functional electrical stimulation therapy assisted walking after chronic motor incomplete spinal cord injury: effects on bone biomarkers and bone strength.
Craven BC; Giangregorio LM; Alavinia SM; Blencowe LA; Desai N; Hitzig SL; Masani K; Popovic MR
J Spinal Cord Med; 2017 Nov; 40(6):748-758. PubMed ID: 28929919
[TBL] [Abstract][Full Text] [Related]
18. Differences in bone mineral density, markers of bone turnover and extracellular matrix and daily life muscular activity among patients with recent motor-incomplete versus motor-complete spinal cord injury.
Kostovski E; Hjeltnes N; Eriksen EF; Kolset SO; Iversen PO
Calcif Tissue Int; 2015 Feb; 96(2):145-54. PubMed ID: 25539858
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.
Malluche HH; Davenport DL; Cantor T; Monier-Faugere MC
Clin J Am Soc Nephrol; 2014 Jul; 9(7):1254-62. PubMed ID: 24948144
[TBL] [Abstract][Full Text] [Related]
20. Effect of chronic activity-based therapy on bone mineral density and bone turnover in persons with spinal cord injury.
Astorino TA; Harness ET; Witzke KA
Eur J Appl Physiol; 2013 Dec; 113(12):3027-37. PubMed ID: 24097172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
